focus -WSS

focus

author：Wikipedia 2025-09-28 01:39:56 - browse：45

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Maisha Meds is a PBM, but don't call it that

WSS

Average age of first period drops to 11.9 years, study shows

A pediatrician calls for Congress to pass the child tax credit deal

There's an unseen cost to disruptive road

HPV vaccine, cervical cancer study delivers historic results

Pumping milk in bathrooms at health conferences is common

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

focus

focus

hotspot

In age of alternative facts, a scholarly course on calling out crap

Dog Aging Project founders on what lies ahead after losing funding

In Memoriam: Notable people who died in 2023

The inclusion problem at the heart of rehabilitation research

Novavax promises a turnaround & Lilly roils the obesity market

Heat waves linked to early deliveries, preterm births in new study

Walensky prepares to leave CDC — and Congress — behind

Do more moles mean more problems? Not so, says new study

Anesthesiologist group: stop taking Ozempic before surgery

First Opinion Podcast: What happens when kids become caregivers?

knowledge

Do more moles mean more problems? Not so, says new study

Prosthetic arm enables patients to feel the objects they grip

Mass General, Mayo Clinic look to monetize custom

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

There's an unseen cost to disruptive road

Biohaven protein

focus

entertainment

entertainment

explore